PF-509783 (32 mg/kg, s.c.) administered in conjunction with haloperidol or vehicle increased cGMP levels in both brain regions, but the effect did not reach statistical significance in the hippocampus.
← all excerpts
Phosphodiesterase 9A in Brain Regulates cGMP Signaling Independent of Nitric-Oxide.
1
—
—